Pharmacokinetics of the Urokinase Receptor-Derived Peptide UPARANT After Single and Multiple Doses Administration in Rats.

摘要: Background and objectives UPARANT has emerged as a novel therapeutic agent with the potential to treat ocular diseases assessed by studies in animal models. Since limited information is available on pharmacokinetics of UPARANT, aim this study evaluate its after single multiple ascending dose (SAD MAD) administration rats. Methods Male (n = 27) female Sprague-Dawley rats were divided into six groups 9/sex/group). was administered via subcutaneous injection (10, 50 or 100 mg/kg; day 1) mg/kg/day; 7 consecutive days; 7) dosing. Blood samples collected 1 (pre-dose, 0.5, 1, 2, 4, 8 24 h post dose) 8, 24, 48 192 dose). The plasma concentration determined validated liquid chromatography mass spectrometry method. Results concentration-time profiles similar SAD MAD both male compound reached maximum (Cmax) at 1-2 slow apparent clearance moderate volume distribution. Moreover, revealed non-proportional increase Cmax area under curve (AUCinf), whereas dose-proportional AUCinf shown administration. Regarding extent accumulation, data suggest negligible accumulation administrations. Conclusion not sex-related, there days treatment. However, exhibited no